BYE-LAWS FOR THE DEGREE OF MASTER OF SCIENCE - M.SC. - UNDER THE AUSPICES OF THE CENTRE FOR MOLECULAR MEDICINE AND

MASTER OF SCIENCE - M.SC. - UNDER THE AUSPICES

OF THE CENTRE FOR MOLECULAR MEDICINE AND

BIOBANKING

SUBSIDIARY LEGISLATION 327.697

BYE-LAWS FOR THE DEGREE OF MASTER OF

SCIENCE - M.SC. - UNDER THE AUSPICES OF THE

CENTRE FOR MOLECULAR MEDICINE AND

BIOBANKING

18th April, 2023

LEGAL NOTICE 90 of 2023.

(1)

These bye-laws may be cited as the Bye-Laws for

the degree of Master of Science - M.Sc. - under the auspices of the

Centre for Molecular Medicine and Biobanking.

(2)

In these bye-laws, unless the context otherwise requires -

“the Board” means the Board of the Centre for Molecular

Medicine and Biobanking;

“the Course” means the programme of study leading to the

degree of Master of Science - M.Sc.;

“the Board of Studies” means the Board of Studies appointed by

Senate for the Course, on the recommendation of the Board.

“the Degree” means the degree of Master of Science - M.Sc.;

and

“the Principal Regulations” means the General Regulations for

University Postgraduate Awards, 2021.

These bye-laws shall be

applicable

for

courses

commencing in February 2023 or later.

Subject to approval by Senate and to the availability of

resources, the Course shall be offered in any area of study related to

Molecular Medicine and Biobanking in which the Centre can offer

expert guidance and supervision. The Board shall announce the areas

of study/areas of specialization, at the time of the call for

applications.

(1)

The Course shall be open to applicants in

possession of a first cycle degree obtained with at least a Second

Class (Honours) or Category II classification, in an area related to the

life sciences or any other area of study deemed relevant by the board.

(2)

Applicants whose first degree was obtained more than 10

years previous to their application for the Course may also be

admitted, provided that they produce sufficient proof of their

MASTER OF SCIENCE - M.SC. - UNDER THE AUSPICES

OF THE CENTRE FOR MOLECULAR MEDICINE AND

BIOBANKING

competence to follow the Course with profit.

The Course shall extend over three semesters of full-time

study or the equivalent in part-time study.

(1)

The programme of study shall comprise study-units

to which a total of 90 ECTS credits are assigned, of which 85 ECTS

credits are assigned to the dissertation study-unit and 5 ECTS credits

are assigned to a taught study-unit.

(2)

The programme of study shall be published after approval

by Senate, normally not less than eight months prior to the

commencement of the Course.

The assessment of the taught study-unit shall be held by

the end of the semester in which the teaching of the study-unit is

held.

(1)

Students shall be required to submit an individual

dissertation of approximately 40,000 words in accordance with the

guidelines issued by the Board.

(2)

The provisional title of the dissertation and a detailed

research proposal shall be submitted to the Board for approval at the

time of the call for applications.

(3)

Work on the dissertation may be undertaken at any time

during the Course after approval of the research proposal. Each

student shall be assigned a principal supervisor, and if necessary a

co-supervisor, who shall provide guidance and advice on a regular

basis during the period of study.

(1)

Students shall be required to report to their

supervisors at least once a month, and in addition as often as the

supervisor deems necessary.

(2)

At the end of each semester of studies, supervisors shall

submit to the Board of Studies progress reports for the students under

their supervision. Students shall seek approval from the Board of

Studies through their supervisor for any substantial modification in

the title or content of the dissertation.

(3)

The Board of Studies shall periodically inform the Board,

in writing, on the general performance of each student. Such reports

may include a recommendation to either (a) extend the period of

study in order to enable the student to complete the dissertation; or

(b) terminate studies prematurely if the principal supervisor deems

this to be proper in the circumstances, provided that

MASTER OF SCIENCE - M.SC. - UNDER THE AUSPICES

OF THE CENTRE FOR MOLECULAR MEDICINE AND

BIOBANKING

(i)

the extension of the study period referred to in (a)

shall be in accordance with the provisions of the

Principal Regulations; and

(ii)

the Board may not terminate studies prematurely

according to (b) until it has first given the student a

chance to be heard.

The Final Weighted Average Mark for the purpose of the

classification of the Degree shall be based on the results obtained in

all the components of the programme of study, all credits being

weighted equally.

The provisions of the foregoing bye-laws shall apply

mutatis mutandis to courses followed on a part-time basis, and

subject to such changes as may reasonably be deemed by the Board

as necessary due to the part-time nature of the Course.